MRK - Merck & Co., Inc.
71.15 +0.05 (0.07%)
After hours: 6:10PM EDT
| Previous Close | 70.78 |
| Open | 70.91 |
| Bid | 68.94 x 900 |
| Ask | 0.00 x 900 |
| Day's Range | 70.90 - 71.57 |
| 52 Week Range | 52.83 - 71.57 |
| Volume | 17,033,118 |
| Avg. Volume | 8,174,756 |
| Market Cap | 189.093B |
| Beta | 1.06 |
| PE Ratio (TTM) | 146.60 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.92 (2.74%) |
| Ex-Dividend Date | 2018-09-14 |
| 1y Target Est | N/A |
- Zacks•11 hours ago
Galectin's GR-MD-02 Positive in Phase Ib Study With Keytruda
Galectin Therapeutics (GALT) posts favorable results from a phase Ib study on GR-MD-02 combined with Merck's Keytruda for treating metastatic melanoma.
Market Realist•12 hours agoNew Indications Are Expected to Drive Future Growth of Keytruda
According to Goldman Sachs analyst Jami Rubin, Merck’s (MRK) Keytruda can earn annual revenues as high as $16.0 billion by 2025. Credit Suisse expects the drug to report peak sales of about $10.0 billion by 2023. According to Trefis estimates, Keytruda is expected to attain peak sales of ~$8.0 billion going forward.
- Market Realist•13 hours ago
Keytruda Is a Major Growth Asset for Merck in 2018
In the first half of the year, Keytruda accounted for 15.27% of Merck’s (MRK) total revenues. Keytruda earned more than 40.0% of its total sales from international markets, despite the company having launched the drug only as a monotherapy and not as a combination regimen in these markets. By the end of the first half of the year, Keytruda was earning 60.0%–65.0% of its revenues from sales to lung cancer patients.
Market Realist•15 hours agoWhy Merck Stock Has Risen 28.2% Year-to-Date
Merck (MRK) stock has risen from $54.93 on January 2 to $70.42 on September 18—a 28.2% increase year-to-date. The performance of Merck stock has been closely related to the sales, clinical trial outcomes, and regulatory decisions for the company’s leading immuno-oncology drug, Keytruda. Approved in 13 indications and eight tumor types, Keytruda reported sales of $1.7 billion in the second quarter.
- Motley Fool•22 hours ago
How Do Drugs Compete Against Each Other?
Investors can keep an eye on these four factors to tell which drugs will out-compete the rest.
- American City Business Journals•yesterday
Flexible labs, co-working space: Big Pharma is rethinking real estate
At an industry event Thursday, representatives from both Merck & Co. and Bristol-Myers Squibb stressed the importance of flexibility in real-estate assets.
- Zacks•yesterday
Merck or Pfizer: Which is the Better Large-Cap Pharma Stock?
In the Large-cap pharma sector, Merck (MRK) and Pfizer (PFE) are two of the biggest names.
- Market Realist•yesterday
Pharma Stocks: GlaxoSmithKline’s Revenue Trend and 2018 Estimates
GlaxoSmithKline reported a nearly flat top line at 7.3 billion pounds, including a 4% rise in operating revenue offset by a 4% negative foreign exchange impact. GlaxoSmithKline’s business is divided into three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare.
- MarketWatch•2 days ago
Galectin stock lifts 15% premarket on early cancer combination trial results
Galectin Therapeutics Inc. shares surged 15% in Thursday premarket trade after the company said that combining its therapy, GR-MD-02, with Keytruda, Merck & Co.'s leading cancer therapy, appeared to have better results for patients with advanced melanoma than Keytruda alone. Notably, though, results were preliminary, based on data from an early-stage, phase 1b clinical trial, and integrated results from two earlier groups of patients on lower doses of GR-MD-02 with a third, higher-dose group. Galectin said that of 14 patients across the three groups, seven had reductions in cancer tumor size, or an objective response rate of 50%. Meanwhile, Keytruda alone has response rate that ranges between 21% to 39%, noted Dr. Brendan Curti, the trial's principal investigator and the director of the Providence Cancer Institute's melanoma program. Of the trial's 14 patients, nine had their cancer improve or remain stable, or a disease control rate of 64%. The phase 1b trial also enrolled six patients with head and neck cancer, for whom a 33% objective response rate and 67% disease control rate were observed. Curti said he and others were "very encouraged" by the melanoma results, and noted that results in both cancers were better than expected for Keytruda on its own. The trial will move forward in both areas, he said, and they plan to include more patients. Galectin shares have dropped nearly 24% over the last three months, compared with a 5.1% rise in the S&P 500 and a 7.1% rise in the Dow Jones Industrial Average .
Market Realist•2 days agoHow Accenture’s Partnership with Merck Could Be Helpful
Accenture (ACN) has teamed up with Merck & Co. (MRK), one of the leading pharmaceutical giants outside the United States, to drive production, effectiveness, and innovation in the initial stages of drug development. Both companies have included Amazon’s (AMZN) AWS (Amazon Web Services) cloud computing, The involvement of the leading public cloud service provider should allow MSD to introduce a cloud-based informatics research platform to support the life sciences industry related to drug manufacturing.
- GuruFocus.com•2 days ago
Merck & Co Inc (MRK) Chairman, President & CEO Kenneth C Frazier Sold $19. ...
Chairman, President & CEO of Merck & Co Inc (NYSE:MRK) Kenneth C Frazier sold 279,851 shares of MRK on 09/18/2018 at an average price of $70.08 a share.
Market Realist•3 days agoCan Accenture Meet Its Operating Margin Guidance in Q4 2018?
Accenture (ACN) has forecast its operating margin for fiscal 2018 at 14.8%, which would be higher than its fiscal 2017 margin of 12.9%. In the past five quarters, it mostly sustained a double-digit operating margin. In the chart below, you can see its GAAP operating margin trend in the last five quarters.
- Market Realist•3 days ago
Pharma Stocks in Review: A Valuation Comparison
In this article, we’ll compare the valuations of Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).
- Zacks•3 days ago
Accenture, Merck & Amazon AWS Partner for Cloud Platform
Accenture's (ACN) latest partnership is likely to boost its Products segment.
- MarketWatch•3 days ago
Health care ETF surges toward record in a broad sector rally
The SPDR Health Care Select Sector ETF rose 0.7% toward a record high in afternoon trade Tuesday, with 55 of its 63 equity components gaining ground. Among the ETF's (XLV) members which are also Dow Jones Industrial Average components, Pfizer Inc.'s stock shot up 1.5%, putting it on track to close at the highest level since December 2001. Also, shares of Johnson & Johnson gained 0.6% toward an eight-month high, Merck & Co. Inc. tacked on 0.4% to sit just shy of its 17-year high reached last Thursday, and UnitedHealth Group Inc. slipped 0.1% and was 2.2% below its Sept. 6 record close of $269.65. The XLV's biggest gainer was Abiomed Inc.'s stock , which rallied 2.7%, while its biggest decliner was AbbVie Inc.'s stock , which shed 2.1% after California sued the company alleging the payment of illegal kickbacks. The XLV has rallied 11% over the past three months, while the Dow has tacked on 5.2%.
- Market Realist•3 days ago
A Review of Pharma Stocks’ EPS Growth Rates
In this article, we’ll compare the EPS growth rates of pharmaceutical companies Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).
- Market Realist•4 days ago
Exploring Pharmaceutical Stocks’ Revenue Growth Rates
In this article, we’ll compare the revenue growth rates of the pharmaceutical companies under review in this series: Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).
- Zacks•4 days ago
Can Pfizer (PFE) Bank on Bavencio for Long-Term Growth?
Pfizer's (PFE) latest anti-PD-L1 immunotherapy, Bavencio, is being touted as a significant long-term top-line driver for the company.
- Market Realist•4 days ago
A Look at the Dividends Paid by Pharma Stocks in 2018
In this article, we’ll discuss the details of the dividends paid by pharmaceutical stocks Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).
Market Realist•4 days agoDelstrigo, Pifeltro, and Merck’s Antiviral Therapy Portfolio
In the second quarter, Merck’s (MRK) Zepatier and Isentress reported revenues of $113.0 million and $305.0 million, respectively, which represented an ~78.0% decline and 8.0% growth on a YoY (year-over-year) basis. In the first half, Zepatier and Isentress reported net revenues of $243.0 million and $586.0 million, respectively.
- Market Realist•4 days ago
A Look at the Market Caps of the Pharma Stocks under Review
As we discussed earlier, a few of the pharmaceutical stocks that have surpassed the returns of the S&P 500 Index YTD (year-to-date) include Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK). Let’s take a look at the details of their market caps.
- Market Realist•4 days ago
How Pharmaceutical ETFs Have Performed in 2018
Pharmaceutical ETFs are securities that are publicly traded on stock markets designed for investors who don’t have the capacity to hold many stocks but are interested in diversification within the pharmaceutical sector.
Market Realist•4 days agoLenvima Could Significantly Boost Merck’s Revenue Growth
In August, the FDA approved Merck’s (MRK) and Eisai’s Lenvima in the first-line setting for the treatment of individuals with unresectable hepatocellular carcinoma (or HCC). The FDA’s approval of Lenvima in the first-line setting for the treatment of HCC was based on data from the REFLECT trial.
- Market Realist•5 days ago
Keytruda Could Boost Merck’s Revenue Growth in 2018 and Beyond
On September 12, Merck (MRK) announced that the FDA accepted for review the company’s new supplemental Biologics License Application (or sBLA) for the label expansion of Keytruda. Merck seeks label expansion of Keytruda for approval as a monotherapy in the first-line setting. This treatment is intended for individuals with metastatic nonsquamous or squamous NSCLC (non-small cell lung cancer) with tumors expressing PD-L1 without EGFR or ALK genomic tumor abnormalities.
- Market Realist•5 days ago
How Is Merck’s Keytruda Positioned in September?
Merck’s (MRK) Keytruda has witnessed ~89% YoY (year-over-year) growth and generated second-quarter revenues of $1.7 billion. In the US market, Keytruda’s second-quarter revenues grew 73.0% to reach $959.0.0 million. In the international markets, Keytruda’s revenues increased ~118.0% YoY to reach $707.0.0 million.
